Citations

Clear

750 citation(s) found for "Lowe, Val".

Longitudinally Increasing Elevated Asymmetric Flortaucipir Binding in a Cognitively Unimpaired Amyloid-Negative Older Individual
Schwarz, Christopher G., Knopman, David S., Ramanan, Vijay K., Lowe, Val J., Wiste, Heather J., Cogswell, Petrice M., Utianski, Rene L., Senjem, Matthew L., Gunter, Jeffrey R., Vemuri, Prashanthi, Petersen, Ronald C., Jack, Clifford R., Jack, Clifford R. , Senjem, Matthew L. , Vemuri, Prashanthi , Jack, Clifford R , Vemuri, Prashanthi , Senjem, Matthew L , Schwarz, Christopher G., Knopman, David S., Ramanan, Vijay K., Lowe, Val J., Wiste, Heather J., Cogswell, Petrice M., Utianski, Rene L., Gunter, Jeffrey R., Petersen, Ronald C.

Mayo Clinic

Journal of Alzheimer's Disease | November 9, 2021 | Volume: 85 | Issue: 1 | Pages: 59-64

10.3233/jad-215052 | PMID 34776445 Get It

We present the case of a cognitively unimpaired 77-year-old man with elevated, asymmetric, and longitudinally increasing Flortaucipir tau PET despite normal (visually negative) amyloid PET. His atypical tau PET signal persisted and globally increased in a follow-up scan five years later. Across eight years of observations, temporoparietal atrophy was observed consistent with tau PET patterns, but he retained the cognitively unimpaired classification. Altogether, his atypical tau PET signal is not explained by any known risk factors or alternative pathologies, and other imaging findings were not remarkable. He remains enrolled for further observation.
Semimechanistic Population Pharmacokinetic Modeling to Investigate Amyloid Beta Trafficking and Accumulation at the BBB Endothelium
Sharda, Nidhi, Curran, Geoffry L., Lowe, Val J. , Kandimalla, Karunya K. , Wang, Zengtao , Kandimalla, Karunya K , Wang, Zengtao , Li, Ling

Mayo Clinic

Molecular Pharmaceutics | October 20, 2021 | Volume: 18 | Issue: 11 | Pages: 4148-4161

10.1021/acs.molpharmaceut.1c00549 | PMID 34664956 Get It

Prognostic role of 11C‐choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy
Jimbo, Masaya , Andrews, Jack R. , Ahmed, Mohamed E. , Dundar, Ayca , Karnes, R. Jeffrey , Bryce, Alan H. , Kwon, Eugene D., Lowe, Val J. , Bold, Michael S., Bryce, Alan H , Kendi, Ayse T, Ahmed, Mohamed , Kendi, A. Tuba

Mayo Clinic

The Prostate | October 14, 2021 | Volume: 82 | Issue: 1 | Pages: 41-48

10.1002/pros.24246 | PMID 34633087 Get It

AbstractBackgroundWe sought to assess the prognostic utility of 11C‐choline positron emission tomography/computed tomography (PET/CT) in patients with metastatic castrate resistant prostate cancer (mCRPC) undergoing primary docetaxel chemotherapy.MethodsWe performed a single institution retrospective analysis of 77 mCRPC patients who were treated with 6 cycles of docetaxel chemotherapy, and who also underwent 11C‐choline PET/CT scans at baseline (before chemotherapy), mid‐course (after 3 cycles), and posttherapy (after 6 cycles). We evaluated treatment response based on percent change in blood pool‐corrected maximum standardized uptake value (SUVmax) of the target lesion on PET/CT, as well as percent change in serum prostate specific antigen (PSA). Logistic regression analysis was used to identify factors associated with complete treatment response. Progression free survival (PFS) analysis was performed using log‐rank test and shown on Kaplan–Meier plot.ResultsPercent change in blood pool‐corrected SUVmax on mid‐course scan was a significant predictor of complete response (odds ratio [OR]: 0.98, 95% confidence interval [CI]: 0.96–0.99, p = .0003), whereas percent change in PSA was not (OR: 0.99, 95% CI: 0.99–1.01, p = .6025). 57 of 77 patients (74%) achieved ≥20% reduction in blood pool‐corrected SUVmax on mid‐course; these patients were 3.6 times more likely to achieve complete response after full 6 cycles of docetaxel chemotherapy, compared to patients with <20% reduction in blood pool‐corrected SUVmax (OR: 3.56, 95% CI: 1.04–16.52, p = .0420). Median PFS in the complete response group was 35.1 months (95% CI: 26.0–52.7 months), compared to 9.4 months (95% CI: 6.9–13.0 months) in the incomplete response group (p = .0005).ConclusionsOur study showed that mid‐course and posttherapy 11C‐choline PET/CT evaluation for mCRPC patients undergoing primary docetaxel chemotherapy can predict full course treatment response and PFS, respectively. 11C‐choline PET/CT imaging may provide valuable prognostic information to guide treatment choices for patients with mCRPC.
Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer
Zhang, Henan , Orme, Jacob J. , Abraha, Feven , Stish, Bradley J. , Lowe, Val J. , Tryggestad, E., Bold, Michael S., Pagliaro, Lance C. , Choo, C. Richard, Brinkmann, Debra H. , Iott, Matthew J., Quevedo, J. Fernando , Harmsen, William S. , Costello, Brian A. , Johnson, Geoffrey B. , Nathan, Mark A., Olivier, Kenneth R. , Pisansky, Thomas M. , Kwon, Eugene D., Tryggestad, Erik J, Brinkmann, Debra H , Davis, Brian J. , Costello, Brian A , Johnson, Geoffrey B , Dong, Haidong , Park, Sean S , Lucien, Fabrice , Dong, Haidong , Park, Sean S.

Mayo Clinic

Clinical Cancer Research | September 30, 2021 | Volume: 27 | Issue: 23 | Pages: 6376-6383

10.1158/1078-0432.ccr-21-2510 | PMID 34593526 Get It

Abstract Purpose: Outcomes for resistant metastatic castration-resistant prostate cancer (CRPC) are poor. Stereotactic ablative radiotherapy (SABR) induces antitumor immunity in clinical and preclinical studies, but immunologic biomarkers are lacking. Patients and Methods: Eighty-nine patients with oligometastatic CRPC were identified by 11C-Choline-PET (Choline-PET) from August 2016 to December 2019 and treated with SABR. Prespecified coprimary endpoints were 2-year overall survival (OS) and PSA progression. Secondary endpoints included 2-year SABR-treated local failure and 6-month adverse events. Correlative studies included peripheral blood T-cell subpopulations before and after SABR. Results: 128 lesions in 89 patients were included in this analysis. Median OS was 29.3 months, and 1- and 2-year OS were 96% and 80%, respectively. PSA PFS was 40% at 1 year and 21% at 2 years. Local PFS was 84.4% and 75.3% at 1 and 2 years, respectively, and no grade ≥3 AEs were observed. Baseline high levels of tumor-reactive T cells (TTR; CD8+CD11ahigh) predicted superior local, PSA, and distant PFS. Baseline high levels of effector memory T cells (TEM; CCR7−CD45RA−) were associated with improved PSA PFS. An increase in TTR at day 14 from baseline was associated with superior OS. Conclusions: This is the first comprehensive effector T-cell immunophenotype analysis in a phase II trial before and after SABR in CRPC. Results are favorable and support the incorporation of immune-based markers in the design of future randomized trials in patients with oligometastatic CRPC treated with SABR.
APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia
Liu, Chia‐Chen , Murray, Melissa E. , Li, Xia , Zhao, Na , Wang, Na , Shue, Francis , Martens, Yuka A. , Li, Yonghe , Raulin, Ana‐Caroline , Rosenberg, Cassandra L. , Doss, Sydney V. , Wren, Melissa C. , Jia, Lin , Ren, Yingxue , Ikezu, Tadafumi C. , Lü, Wenyan, Trottier, Zachary A. , Chen, Yixing , Linares, Cynthia , Wang, Xue , Kurti, Aishe, Asmann, Yan W. , Vemuri, Prashanthi , Kantarci, Kejal , Lowe, Val J. , Jack, Clifford R. , Parisi, Joseph E., Ferman, Tanis J. , Graff‐Radford, Neill R. , Petersen, Ronald C. , Younkin, Steven G. , Fryer, John Denis , Frieden, Carl , Ross, Owen A. , Bu, Guojun , Shue, Francis , Atagi, Yuka , Raulin, Ana-Caroline , Doss, Sydney V , Zhao, Jing , Wren, Melissa C , Ikezu, Tadafumi C , Caulfield, Thomas R , Trottier, Zachary A , Wszolek, Z.K. , Smith, Glenn E. , Vemuri, Prashanthi , Jack, Clifford R , Ferman, Tanis J , Boeve, Brad , Petersen, Ronald C , Younkin, Steven , Frieden, Carl , Dickson, Dennis W , Ross, Owen A , Bu, Guojun , Liu, Chia-Chen , Kantarci, Kejal , Murray, Melissa E , Zhao, Na , Chen, Yixing , Heckman, Michael G. , Zhao, Jing , Fu, Yuan , Caulfield, Thomas R. , Knight, Joshua A. , Wszołek, Zbigniew K. , Knopman, David S. , Boeve, Bradley F. , Wang, Hu , Han, Xianlin , Dickson, Dennis W.

Mayo Clinic

Science Translational Medicine | September 29, 2021 | Volume: 13 | Issue: 613 | Pages: No page available

10.1126/scitranslmed.abc9375 | PMID 34586832 Get It

A rare APOE variant APOE3 -Jac reduces self-aggregation and promotes healthy brain aging.
Deep learning-based brain age prediction in normal aging and dementia
Lee, Jeyeon , Burkett, Brian J. , Senjem, Matthew L. , Lundt, Emily S. , Botha, Hugo, Graff‐Radford, Jonathan , Barnard, Leland R , Gunter, Jeffrey L. , Schwarz, Christopher G. , Lowe, Val J. , Petersen, Ronald C. , Jones, David, Schwarz, Christopher G , Senjem, Matthew L , Burkett, Brian , Min, Hoon-Ki Paul , Kantarci, Kejal , Knopman, David S. , Boeve, Bradley F. , Jack, Clifford R. , Jones, David, Lundt, Emily S

Mayo Clinic

No container title available | August 24, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-804454/v1 Get It

Abstract Normal brain aging is accompanied by patterns of functional and structural change. Alzheimer's disease (AD), a representative neurodegenerative disease, has been linked to accelerated brain aging at respective age ranges. Here, we developed a deep learning-based brain age prediction model using fluorodeoxyglucose (FDG) PET and structural MRI and tested how the brain age gap relates to degenerative cognitive syndromes including mild cognitive impairment, AD, frontotemporal dementia, and Lewy body dementia. Occlusion analysis, performed to facilitate interpretation of the model, revealed that the model learns an age- and modality-specific pattern of brain aging. The elevated brain age gap in dementia cohorts was highly correlated with the cognitive impairment and AD biomarker. However, regions generating brain age gaps were different for each diagnosis group of which the AD continuum showed similar patterns to normal aging in the CU.
Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy
Tosakulwong, Nirubol , Weigand, Stephen D. , Ali, Farwa , Pham, Nha Trang Thu, Senjem, Matthew L. , Jack, Clifford R. , Lowe, Val J. , Ahlskog, J. Eric , Josephs, Keith A. , Whitwell, Jennifer L. , Josephs, Keith A , Whitwell, Jennifer , Jack, Clifford R , Senjem, Matthew L , Clark, Heather M. , Botha, Hugo , Schwarz, Christopher G. , Reid, Robert I.

Mayo Clinic

Movement Disorders | August 24, 2021 | Volume: 36 | Issue: 11 | Pages: 2669-2675

10.1002/mds.28731 | PMID 34426998 Get It

AbstractBackgroundDysphagia is a common symptom of progressive supranuclear palsy often leading to aspiration pneumonia and death.ObjectiveThe aim of this study was to examine how impairments of the oral and pharyngeal phases of the swallow and airway incursion during liquid swallows relate to gray and white matter integrity.MethodsThirty‐eight participants with progressive supranuclear palsy underwent videofluorographic swallowing assessment and structural and diffusion tensor head magnetic resonance imaging. Penalized linear regression models assessed relationships between swallowing metrics and regional gray matter volumes and white matter fractional anisotropy and mean diffusivity.ResultsOral phase impairments were associated with reduced superior parietal volumes and abnormal diffusivity in parietal and sensorimotor white matter, posterior limb of the internal capsule, and superior longitudinal fasciculus. Pharyngeal phase impairments were associated with disruption to medial frontal lobe, corticospinal tract, and cerebral peduncle. No regions were predictive of airway incursion.ConclusionsDifferential patterns of neuroanatomical impairment corresponded to oral and pharyngeal phase swallowing impairments. © 2021 International Parkinson and Movement Disorder Society
Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET
Townley, Ryan , Botha, Hugo , Graff‐Radford, Jonathan , Whitwell, Jennifer , Boeve, Bradley F. , Fields, Julie A. , Drubach, Daniel A., Savica, Rodolfo , Petersen, Ronald C. , Lowe, Val J. , Jack, Clifford R. , Josephs, Keith A. , Townley, Ryan A , Jack, Clifford R , Josephs, Keith A , Boeve, Brad , Botha, Hugo , Machulda, Mary M. , Senjem, Matthew L. , Knopman, David S. , Jones, David T.

Mayo Clinic

Brain Communications | August 17, 2021 | Volume: 3 | Issue: 4 | Pages: No page available

10.1093/braincomms/fcab182 | PMID 34805993 Get It

Abstract Posterior cortical atrophy is a neurodegenerative syndrome with a heterogeneous clinical presentation due to variable involvement of the left, right, dorsal and ventral parts of the visual system, as well as inconsistent involvement of other cognitive domains and systems. 18F-fluorodeoxyglucose (FDG)-PET is a sensitive marker for regional brain damage or dysfunction, capable of capturing the pattern of neurodegeneration at the single-participant level. We aimed to leverage these inter-individual differences on FDG-PET imaging to better understand the associations of heterogeneity of posterior cortical atrophy. We identified 91 posterior cortical atrophy participants with FDG-PET data and abstracted demographic, neurologic, neuropsychological and Alzheimer’s disease biomarker data. The mean age at reported symptom onset was 59.3 (range: 45–72 years old), with an average disease duration of 4.2 years prior to FDG-PET scan, and a mean education of 15.0 years. Females were more common than males at 1.6:1. After standard preprocessing steps, the FDG-PET scans for the cohort were entered into an unsupervised machine learning algorithm which first creates a high-dimensional space of inter-individual covariance before performing an eigen-decomposition to arrive at a low-dimensional representation. Participant values (‘eigenbrains’ or latent vectors which represent principle axes of inter-individual variation) were then compared to the clinical and biomarker data. Eight eigenbrains explained over 50% of the inter-individual differences in FDG-PET uptake with left (eigenbrain 1) and right (eigenbrain 2) hemispheric lateralization representing 24% of the variance. Furthermore, eigenbrain-loads mapped onto clinical and neuropsychological data (i.e. aphasia, apraxia and global cognition were associated with the left hemispheric eigenbrain 1 and environmental agnosia and apperceptive prosopagnosia were associated with the right hemispheric eigenbrain 2), suggesting that they captured important axes of normal and abnormal brain function. We used NeuroSynth to characterize the eigenbrains through topic-based decoding, which supported the idea that the eigenbrains map onto a diverse set of cognitive functions. These eigenbrains captured important biological and pathophysiologic data (i.e. limbic predominant eigenbrain 4 patterns being associated with older age of onset compared to frontoparietal eigenbrain 7 patterns being associated with younger age of onset), suggesting that approaches that focus on inter-individual differences may be important to better understand the variability observed within a neurodegenerative syndrome like posterior cortical atrophy.
Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes
Frank, Ryan D. , Dage, Jeffrey L. , Jeromin, Andreas, Ashton, Nicholas J. , Blennow, Kaj , Karikari, Thomas K. , Vanmechelen, Eugeen , Lowe, Val J. , Bu, Guojun , Vemuri, Prashanthi , Graff‐Radford, Jonathan , Jack, Clifford R. , Petersen, Ronald C. , Jack, Clifford R , Vemuri, Prashanthi , Bu, Guojun , Ashton, Nicholas J , Dage, Jeffrey L , Mielke, Michelle M. , Karikari, Thomas K. , Zetterberg, Henrik , Algeciras‐Schimnich, Alicia , Knopman, David S.

Mayo Clinic

JAMA Neurology | July 26, 2021 | Volume: 78 | Issue: 9 | Pages: 1108

10.1001/jamaneurol.2021.2293 | PMID 34309632 Get It